| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.kilitch.com | |
| Market Cap | 332.99 Cr. | |
| Enterprise Value(EV) | 337.44 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 6.28 | Trailing Twelve Months Ending 2022-12 |
| Price-Earning Ratio (PE) | 34.04 | Trailing Twelve Months Ending 2022-12 |
| Industry PE | 31.87 | Trailing Twelve Months Ending 2022-12 |
| Book Value / Share | 93.99 | Trailing Twelve Months Ending 2022-12 |
| Price to Book Value | 2.27 | Calculated using Price: 213.70 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 1.56 Cr. | 15,582,319 Shares |
| FaceValue | 10 | |
| About Kilitch Drugs (India) Ltd. | ||
| Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place. | ||
| 1 Day |
|
+4.29% |
| 1 Week |
|
-2.82% |
| 1 Month |
|
+22.11% |
| 3 Month |
|
+54.80% |
| 6 Month |
|
+30.07% |
| 1 Year |
|
+40.55% |
| 2 Year |
|
+17.74% |
| 5 Year |
|
+137.44% |
| 10 Year |
|
+889.35% |
| 9 years | 2012-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 78.03 | -0.25 | -9.91 | -8.59 | 4.95 | 3.36 | 0.71 | 3.09 | 4.73 | |
| Return on Capital Employed (%) | 76.95 | -0.74 | -10.11 | -8.69 | 6.08 | 7.59 | 1.95 | 4.40 | 7.26 | |
| Return on Assets (%) | 46.26 | -0.19 | -9.25 | -7.86 | 4.36 | 2.85 | 0.59 | 2.19 | 3.03 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 115 | 120 | 109 | 101 | 112 | 121 | 118 | 127 | 139 | 145 | |
| Non Curr. Liab. | 1 | -1 | -1 | -2 | -2 | -1 | -1 | -1 | -1 | -1 | |
| Curr. Liab. | 60 | 7 | 8 | 12 | 15 | 20 | 22 | 73 | 69 | 64 | |
| Minority Int. | 1 | 1 | 2 | 2 | 2 | 1 | 0 | ||||
| Equity & Liab. | 177 | 126 | 116 | 110 | 126 | 143 | 142 | 202 | 208 | 208 | |
| Non Curr. Assets | 10 | 79 | 68 | 62 | 63 | 78 | 86 | 122 | 94 | 104 | |
| Curr. Assets | 167 | 47 | 47 | 49 | 63 | 65 | 56 | 80 | 114 | 104 | |
| Misc. Exp. not W/O | 0 | 0 | |||||||||
| Total Assets | 177 | 126 | 116 | 110 | 126 | 143 | 142 | 202 | 208 | 208 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
| Net Sales | 108 | 19 | 21 | 29 | 51 | 82 | 53 | 69 | 114 | 131 | |
| Other Income | 1 | 3 | 3 | 1 | 3 | 5 | 5 | 3 | 3 | 2 | |
| Total Income | 109 | 22 | 24 | 30 | 54 | 88 | 58 | 71 | 117 | 133 | |
| Total Expenditure | -95 | -21 | -25 | -29 | -46 | -76 | -53 | -63 | -104 | -114 | |
| PBIDT | 14 | 1 | -2 | 1 | 9 | 11 | 5 | 8 | 13 | 19 | |
| Interest | -3 | 0 | 0 | 0 | 0 | -1 | -1 | -1 | -1 | -4 | |
| Depreciation | -5 | -2 | -10 | -10 | -2 | -2 | -2 | -2 | -2 | -4 | |
| Taxation | -21 | 1 | 0 | 0 | -1 | -5 | -1 | -1 | -3 | -3 | |
| Exceptional Items | 92 | ||||||||||
| PAT | 76 | 0 | -11 | -9 | 5 | 4 | 1 | 4 | 6 | 8 | |
| Minority Interest | 1 | 0 | 1 | 2 | |||||||
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | 77 | 0 | -11 | -9 | 5 | 4 | 1 | 4 | 7 | 10 | |
| Adjusted EPS | 58 | 0 | -8 | -7 | 4 | 2 | 1 | 2 | 5 | 6 |
| Particulars | 10 years | 2011-03 Rs. Cr. | 2012-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 22 | -29 | -8 | 17 | 1 | 1 | 0 | 4 | 46 | 6 | |
| Cash Fr. Inv. | -24 | 41 | -31 | -20 | -2 | -4 | -14 | -10 | -38 | -15 | |
| Cash Fr. Finan. | 7 | -9 | 0 | 0 | 0 | 6 | 17 | 1 | 2 | 7 | |
| Net Change | 6 | 2 | -39 | -2 | 0 | 2 | 3 | -5 | 10 | -2 | |
| Cash & Cash Eqvt | 9 | 12 | 5 | 3 | 2 | 5 | 8 | 3 | 13 | 10 |
|
Tue, 23 May 2023
Compliances-Reg.24(A)-Annual Secretarial Compliance Pursuant to Regulation 24A of SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015 please find enclosed herewith Annual Secretarial Compliance Report for the financial year ended 31st March 2023 issued by practicing company secretary Deep Shukla & Associates dated 10th May 2023 |
|
Wed, 17 May 2023
Board Meeting Intimation for Considering The Financial Results For The Quarter And Year Ended 31St March 2023 KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended this is to inform you that the meeting of the Board of Directors of the Company will be held on Monday 29th May 2023 inter-alia to consider and approve the audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended 31st March 2023 |
|
Fri, 12 May 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015 we hereby intimate you that the Company has received letter in relation with loss of Share Certificate from the Registrar and Share Transfer Agents of the Company i.e. Link Intime India Private Limited. Further the request for issue of duplicate share certificate has also been received with respect to the same. |
| Fri, 26 May 2023 |
Closing Above Previous High
|
Close Within 52 Week High Zone
|
Close Above Last Month High
|
High Increase in 1 Month
|
High Increase in 3 Months
|
Equities
M.F.
Sectors
StockEdge Social